Your browser doesn't support javascript.
loading
Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras.
Wheeler, Lee Adam; Vrbanac, Vladimir; Trifonova, Radiana; Brehm, Michael A; Gilboa-Geffen, Adi; Tanno, Serah; Greiner, Dale L; Luster, Andrew D; Tager, Andrew M; Lieberman, Judy.
Afiliação
  • Wheeler LA; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Mol Ther ; 21(7): 1378-89, 2013 Jul.
Article em En | MEDLINE | ID: mdl-23629001
ABSTRACT
The continued spread of HIV underscores the need to interrupt transmission. One attractive strategy, in the absence of an effective vaccine, is a topical microbicide, but the need for application around the time of sexual intercourse leads to poor patient compliance. Intravaginal (IVAG) application of CD4 aptamer-siRNA chimeras (CD4-AsiCs) targeting the HIV coreceptor CCR5, gag, and vif protected humanized mice from sexual transmission. In non-dividing cells and tissue, RNAi-mediated gene knockdown lasts for several weeks, providing an opportunity for infrequent dosing not temporally linked to sexual intercourse, when compliance is challenging. Here, we investigate the durability of gene knockdown and viral inhibition, protection afforded by CCR5 or HIV gene knockdown on their own, and effectiveness of CD4-AsiCs formulated in a gel in polarized human cervicovaginal explants and in humanized mice. CD4-AsiC-mediated gene knockdown persisted for several weeks. Cell-specific gene knockdown and protection were comparable in a hydroxyethylcellulose gel formulation. CD4-AsiCs against CCR5 or gag/vif performed as well as a cocktail in humanized mice. Transmission was completely blocked by CCR5 CD4-AsiCs applied 2 days before challenge. Significant, but incomplete, protection also occurred when exposure was delayed for 4 or 6 days. CD4-AsiCs targeting gag/vif provided some protection when administered only after exposure. These data suggest that CD4-AsiCs are a promising approach for developing an HIV microbicide.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos CD4 / Infecções por HIV / RNA Interferente Pequeno Limite: Animals / Female / Humans Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos CD4 / Infecções por HIV / RNA Interferente Pequeno Limite: Animals / Female / Humans Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos